Evaxion Biotech A/SNASDAQ:EVAXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE2.6300
- TODAY'S CHANGE (%)-0.0500 (-1.8657%)
- Bid / Lots2.4600/ 3
- Ask / Lots2.8200/ 10
- Open / Previous Close2.6600 / 2.6800
- Day Range
- 52 Week Range
- Volume93,743
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | EVAX |
|---|---|---|
| 09:32 ET | 278 | 2.66 |
| 09:41 ET | 1380 | 2.67 |
| 09:52 ET | 750 | 2.7892 |
| 10:01 ET | 1100 | 2.8239 |
| 10:08 ET | 10600 | 2.8299 |
| 10:10 ET | 3403 | 2.82 |
| 10:21 ET | 9459 | 2.42 |
| 10:24 ET | 3531 | 2.8199 |
| 10:26 ET | 1148 | 2.6 |
| 10:28 ET | 4200 | 2.58 |
| 10:30 ET | 1141 | 2.75 |
| 10:32 ET | 1592 | 2.74 |
| 10:33 ET | 2107 | 2.55 |
| 10:35 ET | 2371 | 2.64 |
| 10:37 ET | 3100 | 2.6021 |
| 10:48 ET | 140 | 2.62 |
| 10:50 ET | 1304 | 2.63 |
| 10:51 ET | 1192 | 2.6786 |
| 11:22 ET | 100 | 2.66 |
| 11:44 ET | 1847 | 2.6 |
| 12:03 ET | 433 | 2.59 |
| 12:09 ET | 100 | 2.61 |
| 12:36 ET | 3000 | 2.6101 |
| 01:21 ET | 200 | 2.625 |
| 01:24 ET | 100 | 2.625 |
| 01:53 ET | 200 | 2.62 |
| 02:09 ET | 500 | 2.75 |
| 02:33 ET | 500 | 2.82 |
| 02:54 ET | 2150 | 2.624 |
| 02:58 ET | 2600 | 2.796 |
| 03:07 ET | 100 | 2.61 |
| 03:23 ET | 700 | 2.72 |
| 03:32 ET | 100 | 2.67 |
| 03:38 ET | 633 | 2.65 |
| 03:52 ET | 1932 | 2.63 |
| 03:56 ET | 100 | 2.63 |
| 03:59 ET | 654 | 2.63 |
Yesterday
Strong validation of Evaxion's AI-Immunology(TM) platform in multiple clinical trials, from 8:00AM ET on Wednesday Oct 09, 2024 by Dow Jones
8:00AM ET on Wednesday Oct 09, 2024 by Dow Jones
Oct 3, 2024
Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology(TM) platform, from 8:00AM ET on Thursday Oct 03, 2024 by Dow Jones
8:00AM ET on Thursday Oct 03, 2024 by Dow Jones
Sep 26, 2024
DJ Evaxion Biotech Price Target Maintained With a $14.00/Share by HC Wainwright & Co., from 12:05PM ET on Thursday Sep 26, 2024 by Dow Jones
12:05PM ET on Thursday Sep 26, 2024 by Dow JonesEvaxion significantly expands vaccine development collaboration with MSD, from 7:30AM ET on Thursday Sep 26, 2024 by Dow Jones
7:30AM ET on Thursday Sep 26, 2024 by Dow Jones
Sep 20, 2024
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing, from 8:35AM ET on Friday Sep 20, 2024 by Dow Jones
8:35AM ET on Friday Sep 20, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Evaxion Biotech A/S | 14.9M | -0.1x | --- |
Apollomics Inc | 14.9M | -0.2x | --- |
Imunon Inc | 14.6M | -0.5x | --- |
Inhibitor Therapeutics Inc | 14.6M | -4.8x | --- |
NRX Pharmaceuticals Inc | 15.8M | -0.9x | --- |
Protext Mobility Inc | 15.8M | 0.0x | --- |
Company Information
Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Contact Information
- Headquarters
- Bredgade 34E, Copenhagen KCOPENHAGEN, Denmark 1260
- Phone
- ---
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $14.9M |
|---|---|
Revenue (TTM) | $278.0K |
Shares Outstanding | 557.6K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.24 |
EPS | $-36.98 |
Book Value | $-1.25 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 53.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -6,871.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
